ENTITY
Biogen Inc

Biogen Inc (BIIB US)

144
Analysis
Health CareUnited States
Biogen Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products address diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis.
more
15 Mar 2020 15:42

What Would Warren Buffett Buy In This Panic?

There has been a huge panic in the global financial markets caused by the COVID-19 coronavirus. Some people compare this panic to the one in 2008....

Logo
345 Views
Share
05 Mar 2020 10:35

A Bottom Has Been Established; Possible Retest?

In today’s report we outline  our belief that the combination of extreme oversold conditions and several key sectors/industries holding above major...

Logo
369 Views
Share
bullishS&P 500 INDEX
28 Nov 2019 06:30

U.S. Equity Strategy: Upgrading Health Care to Overweight

Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year...

Logo
379 Views
Share
bullishS&P 500 INDEX
06 Nov 2019 05:30

U.S. Equity Strategy: Small-Caps Testing Critical Resistance; Downgrading Communications

As bullish developments pile up, the weight-of-the-evidence continues to support our belief that we may be in the early stages of a broad-based...

Logo
409 Views
Share
06 Feb 2019 11:41

Biosimilar Battlefield: The Remsima/Inflectra Warning

2019 marks an inflection point for Korean biosimilar companies Celltrion Healthcare (091990 KS), Celltrion Inc (068270 KS), and Samsung Biologics...

Share
x